Accutane - Safety Labeling Revised.

FDA and Roche revised the WARNINGS: Psychiatric Disorders, Boxed
CONTRAINDICATIONS AND WARNINGS, MEDICINAL DRUG AND GOVERNMENT ACTIVITY,
and PRECAUTIONS: Drug Interactions sections of the prescribing accusal.
Changes in pediatric labeling were made to the CLINICAL PHARMACOLOGY:
Television show Affected role Populations: Pediatric Patients,
WARNINGS: Skeletal: Bone Mineral Denseness, and PRECAUTIONS: Pediatric
Use: sections.

Aggressive
and/or violent behaviors have been added to the list of events that
Accutane may reason, based on post-marketing rubber reports.
No carrying into action of natural process has been established for
these events.
A new piece of furniture has been added to clarify those circumstance
where pregnancy tests and Accutane Fittingness Stickers are applicable.
Knowledge medicament to pediatric patients has been added based on the
results of recent studies conducted in this case settlement.
A subject matter has been added regarding the long-term use of Accutane
advising that Accutane be given at the recommended doses for no longer
than the recommended continuance.
This is a part of article Accutane - Safety Labeling Revised. Taken from "Acne Isotretinoin Accutane" Information Blog